By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics today said it has completed its $80 million purchase of Rules-Based Medicine.

RBM will remain based in Austin, Texas and will operate as a wholly owned subsidiary of Myriad. RBM discovers biomarkers for pharmaceutical and biotechnology firms using its multiplex immunoassay technology. It will continue its collaborations with pharma partners in companion diagnostic discovery and carry out internal research projects, Myriad said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.